These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22189152)

  • 1. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy.
    Garvey L; Surendrakumar V; Winston A
    HIV Clin Trials; 2011; 12(6):333-8. PubMed ID: 22189152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.
    Winston A; Puls R; Kerr SJ; Duncombe C; Li PC; Gill JM; Taylor-Robinson SD; Emery S; Cooper DA;
    HIV Med; 2012 Apr; 13(4):245-51. PubMed ID: 22151608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia.
    Ciccarelli N; Fabbiani M; Colafigli M; Trecarichi EM; Silveri MC; Cauda R; Murri R; De Luca A; Di Giambenedetto S
    Antivir Ther; 2013; 18(2):153-60. PubMed ID: 23486721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlations between computerized battery testing and a memory questionnaire for identification of neurocognitive impairment in HIV type 1-infected subjects on stable antiretroviral therapy.
    Garvey LJ; Yerrakalva D; Winston A
    AIDS Res Hum Retroviruses; 2009 Aug; 25(8):765-9. PubMed ID: 19678764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.
    Ciccarelli N; Fabbiani M; Di Giambenedetto S; Fanti I; Baldonero E; Bracciale L; Tamburrini E; Cauda R; De Luca A; Silveri MC
    Neurology; 2011 Apr; 76(16):1403-9. PubMed ID: 21502598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.
    Fabbiani M; Grima P; Milanini B; Mondi A; Baldonero E; Ciccarelli N; Cauda R; Silveri MC; De Luca A; Di Giambenedetto S
    Antivir Ther; 2015; 20(4):441-7. PubMed ID: 25516553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral function tests reveal differences in HIV-infected subjects with and without chronic HCV co-infection.
    Thiyagarajan A; Garvey LJ; Pflugrad H; Maruff P; Scullard G; Main J; Taylor-Robsinson S; Winston A
    Clin Microbiol Infect; 2010 Oct; 16(10):1579-84. PubMed ID: 20132257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients.
    Fabbiani M; Ciccarelli N; Tana M; Farina S; Baldonero E; Di Cristo V; Colafigli M; Tamburrini E; Cauda R; Silveri MC; Grima P; Di Giambenedetto S
    HIV Med; 2013 Mar; 14(3):136-44. PubMed ID: 22994586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients.
    Ciccarelli N; Grima P; Fabbiani M; Baldonero E; Borghetti A; Milanini B; Limiti S; Colafigli M; Tamburrini E; Cauda R; De Luca A; Di Giambenedetto S
    Antivir Ther; 2015; 20(4):433-40. PubMed ID: 25504667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.
    Vassallo M; Durant J; Lebrun-Frenay C; Fabre R; Ticchioni M; Andersen S; DeSalvador F; Harvey-Langton A; Dunais B; Cohen-Codar I; Montagne N; Cua E; Fredouille-Heripret L; Laffon M; Cottalorda J; Dellamonica P; Pradier C
    HIV Med; 2015 Aug; 16(7):431-40. PubMed ID: 25981452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care.
    McCombe JA; Vivithanaporn P; Gill MJ; Power C
    HIV Med; 2013 Feb; 14(2):99-107. PubMed ID: 22994556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurocognitive function in HIV infected patients on antiretroviral therapy.
    Winston A; Arenas-Pinto A; Stöhr W; Fisher M; Orkin CM; Aderogba K; De Burgh-Thomas A; O'Farrell N; Lacey CJ; Leen C; Dunn D; Paton NI;
    PLoS One; 2013; 8(4):e61949. PubMed ID: 23646111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of protease inhibitor-based regimens in HIV-infected Thai children failing first-line treatment.
    Wattanutchariya N; Sirisanthana V; Oberdorfer P
    HIV Med; 2013 Apr; 14(4):226-32. PubMed ID: 23094820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
    AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can antiretroviral therapy prevent HIV-associated cognitive disorders?
    Winston A; Vera JH
    Curr Opin HIV AIDS; 2014 Jan; 9(1):11-6. PubMed ID: 24275675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.